A carregar...
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy
PURPOSE: Addition of rolapitant to standard antiemetic therapy improved protection against chemotherapy-induced nausea and vomiting (CINV) in phase 3 trials of patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). Here, we assessed the impact of CINV on...
Na minha lista:
| Publicado no: | Support Care Cancer |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Berlin Heidelberg
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5127871/ https://ncbi.nlm.nih.gov/pubmed/27557833 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-016-3388-7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|